NASDAQ · PCR
Financial Services · Asset Management - Income
$17.86
Down-$0.05 (-0.28%)
Updated Nov 2, 2026, 9:00 AM
SID Score
3.6/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · PCR
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
PCR closed at $17.86 after 20 trading sessions, down 0.78% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $17.84 | $17.855 | $17.84 | $17.855 | 1.99K |
| Oct 29, 2026 | $17.905 | $17.905 | $17.905 | $17.905 | 7 |
| Oct 28, 2026 | $17.92 | $17.93 | $17.83 | $17.88 | 2.08K |
| Oct 27, 2026 | $17.86 | $17.865 | $17.86 | $17.865 | 800.1 |
| Oct 26, 2026 | $17.875 | $17.875 | $17.875 | $17.875 | 28.06 |
| Oct 23, 2026 | $17.87 | $17.9199 | $17.87 | $17.875 | 608.06 |
| Oct 22, 2026 | $17.89 | $17.89 | $17.89 | $17.89 | 8.94 |
| Oct 21, 2026 | $17.835 | $17.835 | $17.835 | $17.835 | 143 |
| Oct 20, 2026 | $17.8001 | $17.84 | $17.8001 | $17.84 | 291.4 |
| Oct 19, 2026 | $17.78 | $17.83 | $17.78 | $17.83 | 2.15K |
| Oct 16, 2026 | $17.82 | $17.82 | $17.82 | $17.82 | 343 |
| Oct 15, 2026 | $17.50 | $17.96 | $17.50 | $17.8674 | 1.75K |
| Oct 14, 2026 | $17.71 | $17.72 | $17.5747 | $17.5747 | 1.45K |
| Oct 13, 2026 | $17.70 | $17.81 | $17.6601 | $17.7721 | 2.06K |
| Oct 12, 2026 | $17.8918 | $17.8918 | $17.8918 | $17.8918 | 16.41 |
| Oct 9, 2026 | $17.98 | $17.98 | $17.84 | $17.84 | 315 |
| Oct 8, 2026 | $17.79 | $17.9002 | $17.79 | $17.9002 | 780.96 |
| Oct 7, 2026 | $17.68 | $17.765 | $17.68 | $17.765 | 743.05 |
| Oct 6, 2026 | $17.91 | $17.9247 | $17.91 | $17.9247 | 1.2K |
| Oct 5, 2026 | $18.07 | $18.07 | $17.9953 | $17.9953 | 567.96 |
The latest Smart Investors Daily articles mentioning PCR.
Company
Market Activity
Research & News
PCR research
Company profile and research snapshot.
PCR is an actively managed ETF employing two primary strategies: private credit exposure via index tracking, and a long/short equity hedge. The bulk of the assets are invested in publicly-traded business development companies and closed-end funds focused on private credit, as determined by an index. A proprietary scoring methodology for volatility and yield is used to select index holdings, favoring those with lower volatility and higher yield. Positions are weighted by trading volume, and the fund may hold larger allocations in fewer issuers. The index is reconstituted and rebalanced semi-annually. The credit hedging strategy uses total return swaps to go long on quality equities and short junk equities. The fund may take temporary defensive positions during adverse market conditions.
Consensus and target data currently published for this company.
No generated briefing is available yet.
SeekingAlpha · Oct 14, 2026
Recent redemptions from semiliquid direct lending vehicles have tightened financing conditions at the margin, helping lenders regain negotiating power. Read more here.
SeekingAlpha · Sep 14, 2026
Since the 2008 Financial Crisis, BDCs have exploded in popularity as a conduit for private credit for retail and institutional investors alike. Read more here.
Yahoo · Sep 3, 2026
NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Simplify Asset Management Inc. announces that the previously disclosed net asset values (NAVs) per share of the Simplify VettaFi Private Credit Strategy ETF (NYSE Arca: PCR) from March 17 to September 1, 2026 have been restated effective September 3, 2026, as follows: ETF NameTickerDateRevised NAVOriginal NAVAdjustmentSimplify VettaFi Private Credit Strategy ETFPCR3/17/202619.6119.67-0.29% 3/18/202619.5919.65-0.29% 3/19/202619.7219.78-0.29% 3/20/20261
SeekingAlpha · Aug 10, 2026
U.S. fixed income and equity markets saw solid gains last week as a surprisingly weak July employment report sparked a rally in Treasuries.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning PCR.
